Relmada Therapeutics announced the appointment of Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology. This hire is significant as Dr. Jakobsen will lead the planned Phase 3 SPECTRUM registrational program for NDV-01 and brings prior experience with a globally approved gene therapy, which could accelerate Relmada's oncology pipeline development.
Relmada Therapeutics has appointed Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology. This is a positive development for the company as Dr. Jakobsen brings significant experience in clinical development, particularly in oncology, including leading a successful Phase 3 program for a globally approved gene therapy. His expertise is expected to be crucial for advancing Relmada's planned Phase 3 SPECTRUM registrational program for NDV-01 and its broader oncology and CNS pipeline. For traders, this appointment signals a strengthened leadership team, potentially de-risking future clinical trials and regulatory submissions, offering a long-term positive outlook for the stock as the company progresses its pipeline.